

Supplementary Table S3. Distribution of the patients according to the change of treatment based on ctDNA findings.

Alterations in ctDNA	New therapy	# patients
<i>AKT/PIK3CA^a mutation</i>	Everolimus	11
<i>CDK4 amplification</i>	Palbociclib	1
<i>EGFR mutation^a</i>	Erlotinib	1
<i>ESR1 mutation</i>	Chemotherapy	2
<i>Increased number of mutations</i>	Targeted therapy ± endocrine therapy, chemotherapy	5

^a A patient was started on Everolimus based on *AKT1* mutation in ctDNA. When she progressed, she was started on Erlotinib based on *EGFR* mutation in ctDNA.